Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis
NCT06930612Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- May 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CM512 in chronic rhinosinusitis with nasal polyposis (CRSwNP) (4 arms), sponsored by Keymed Biosciences. Primary endpoint: Nasal Polyps Score at 24 weeks. Started May 2025; status: completed.
02
Drugs
CM512
03
Conditions
chronic rhinosinusitis with nasal polyposis (CRSwNP)
Beyond the preview
Go deeper on NCT06930612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06930612.